Prion Surveillance in Primary Immunodeficiency Patients

Home / Projects / All Projects / Prion Surveillance in Primary Immunodeficiency Patients

Prion Surveillance in Primary Immunodeficiency Patients

Principal Investigator: Dr Anna Molesworth

Variant Creutzfeldt-Jakob Disease (vCJD) is a very rare disease, associated with an abnormal form of a naturally occurring protein (the prion protein), the presence of which can be detected in certain body tissues. The Primary Immunodeficiency Study aims to find out whether any evidence of this abnormal prion protein can be found in antibody deficient patients who received certain UK-sourced immunoglobulin products between 1996 & 2000. The products were made from plasma from UK donors and patients treated with these products may have been exposed to vCJD.

The study currently involves immunology teams and patients throughout the UK. Patients involved in the study are followed over several years, testing any available tissue (for example, the tissue left over from routine biopsies) and blood (when a suitable test becomes available) for the abnormal prion protein that causes prion disease. Participants can also agree to donate tissues obtained from a post-mortem, as this is the best way to collect samples that help us confidently state whether prion infection has taken place. In this way we can find out more about the risks that may be associated with past treatment with blood products, which in turn will inform measures to protect public health.

The study was started by the Primary Immunodeficiency Association (PiA) and the UK Primary Immunodeficiency Network in 2006, under the leadership of Dr Matthew Helbert, Consultant Immunologist at Central Manchester University Hospitals NHS Foundation Trust. Following Dr Helbert’s retirement in 2015, management of the study transferred from Manchester to Edinburgh, and is now led by Dr Anna Molesworth (PhD) working with the team at the National Creutzfeldt-Jakob Disease Research & Surveillance Centre (NCJDRSU) in Edinburgh. A recent article about the project and its transfer to Edinburgh can be found here: http://www.piduk.org/whatarepids/treatment/immunoglobulinreplacementtherapy/prioninfectionsurveillanceproject

To date, no evidence has been found to show prion disease. This means that no patients have shown symptoms of prion disease, nor is there any evidence of prion infection in the tissues tested.

Further information can be found at the links below.  Patients and their doctors are also welcome to talk with us about the study, If you would like to find out more please contact Mrs Kudzai Karekwaivanane, Research Assistant on our Study Research Team and we will be happy to help.

Mrs Kudzai Karekwaivanane (Research Assistant)

Telephone: 0131 537 2128  / 07464 677118